Molecular and Clinical Oncology是一本接受开放获取期刊。根据官网显示发表文章类型不同版面费不同,具体如下。 6.期刊接受类型 期刊接受的稿件类型包括原创研究、病例报告和评论文章。 Molecular and Clinical Oncology研究主题包括临床肿瘤学、化疗、致癌基因、转移和病毒肿瘤学。 7.推荐指数 Molecular and Clinical Oncolo...
《分子与临床肿瘤学》(Molecular And Clinical Oncology)是一本以ONCOLOGY综合研究为特色的国际期刊。该刊由Spandidos Publications UK出版商该刊已被国际重要权威数据库SCIE收录。期刊聚焦ONCOLOGY领域的重点研究和前沿进展,及时刊载和报道该领域的研究成果,致力于成为该领域同行进行快速学术交流的信息窗口与平台。该刊2023...
基本信息 期刊全称 Molecular and Clinical Oncology 期刊简称 Print ISSN 2049-9450 Online ISSN 2049-9469 期刊出版社 是否开放获取 Open Access,OA 暂无数据 官网地址 期刊所属领域 期刊简介 JCR分区索引信息2021年数据 是否是SCIE(SCI) 注:SCI已经完全被SCIE取代,参考:SCI被取代 ...
《Molecular And Clinical Oncology》国际简称:MOL CLIN ONCOL,是由出版商Spandidos Publications UK出版的一本致力于发布--研究新成果的的专业学术期刊。主要发表刊登有创见的学术论文文章、行业最新科研成果,扼要报道阶段性研究成果和重要研究工作的最新进展,选载对学
你好 源于网络翻译，仅供参考 MOLECULAR AND CLINICAL ONCOLOGY 分子与临床肿瘤学 重点词汇 MOLECULAR分子的，由分子组成的 CLINICAL ONCOLOGY临床肿瘤学 MOLECULAR AND CLINICAL ONCOLOGY据相关资料目前还不是SCI杂志，据说将来很可能被收录。希望对你有帮助 ...
学科:ONCOLOGY ESCI Q4 276 / 322 14.44% 名词解释: JCR分区是由科睿唯安公司(原汤森路透,2016年易主科睿唯安)每年发布的,设置了254个具体学科,根据每个学科分类按照期刊当年的影响因子高低将期刊平均分为4个区,分别为Q1、Q2、Q3和Q4,各占25%。JCR分区包括自然科学(Science Edition)和社会科学(Social Sciences...
Evolution of the number of total citation per document and external citation per document (i.e. journal self-citations removed) received by a journal's published documents during the three previous years. External citations are calculated by subtracting the number of self-citations from the total...
HER2 and Ki67 was performed by the Department of Pathology of FUSCC. ER/PR negativity was defined as <1% positively stained cells in IHC testing. All pathology results were confirmed independently by two experienced pathologists according to the latest American Society of Clinical Oncology/College of...
More importantly, such an aberrant organ can be maintained and even formed at remote sites if no therapeutic intervention is performed. It is well established that tumor engraftment, although requiring a large number of cells, results in the formation of secondary tumors that reca- pitulate ...
Background: Little information exists about the early, middle and late image effects after antigen-specific multi-peptide immunotherapy and immunomodulation in epithelial ovarian cancer. Most of the potential effects in pseudo-progression and pseudo-relapse are mainly unknown for the oncologists and ...